Plague treatment with moxifloxacin
Yes—use moxifloxacin 400 mg once daily (IV or PO) for 10–14 days to treat plague in a healthy adult. 1, 2
- First-line options for pneumonic/septicemic or bubonic/pharyngeal plague in adults include fluoroquinolones; moxifloxacin 400 mg q24h IV or PO is explicitly recommended; treat 10–14 days 1.
- FDA label: moxifloxacin is approved for treatment and prophylaxis of plague in adults; animal efficacy plus human PK support survival benefit, with 100% survival in an AGM pneumonic plague model at humanized exposures 2.
- Severe disease or bioterrorism exposure: start dual therapy with two different classes initially; moxifloxacin can be one agent (e.g., + aminoglycoside) until stabilized, then continue monotherapy to complete 10–14 days 1.
- Plague meningitis: use dual therapy initially; chloramphenicol plus moxifloxacin, or if chloramphenicol unavailable, add moxifloxacin to existing regimen; continue the full regimen an additional 10 days after adding the second agent 1.
Dosing algorithm (adult, otherwise healthy):
- Uncomplicated bubonic/pharyngeal or stabilized pneumonic/septicemic: moxifloxacin 400 mg q24h IV or PO for 10–14 days 1.
- Severe pneumonic/septicemic or suspected engineered resistance: initiate dual therapy (e.g., moxifloxacin 400 mg q24h + gentamicin 5 mg/kg q24h), then de-escalate once improved; total duration 10–14 days 1.
- If meningitis suspected: dual therapy with chloramphenicol + moxifloxacin 400 mg q24h; continue all agents for an additional 10 days after addition 1.
Key pitfalls and how to avoid them:
- Do not underdose or shorten therapy: use 10–14 days; earlier discontinuation risks relapse and mortality 1.
- QT prolongation risk: avoid/limit coadministration with other QT-prolonging drugs and correct electrolytes; consider alternative fluoroquinolone in high-risk arrhythmia patients 2.
- Pediatric dosing differs and moxifloxacin is off-label in ≤17 years; this plan applies to adults only 1.
- For pneumonic plague infection control, maintain droplet precautions for ≥48 hours of effective therapy with clinical improvement before de-escalation 1.
Why this recommendation maximizes survival and QOL:
- CDC/US HHS 2021 guideline lists moxifloxacin as a first-line regimen with defined dosing and duration across plague syndromes, and recommends dual therapy initially for severe disease to reduce mortality 1.
- FDA approval for plague with robust animal survival data and human PK matching therapeutic exposures supports efficacy and safety in adults, directly targeting morbidity/mortality 2.